Vericel (VCEL) Revenue & Revenue Breakdown
Vericel Revenue Highlights
Latest Revenue (Y)
$197.52M
Latest Revenue (Q)
$52.66M
Main Segment (Y)
MACI Implants And Kits
Vericel Revenue by Period
Vericel Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $197.52M | 20.17% |
| 2022-12-31 | $164.37M | 5.24% |
| 2021-12-31 | $156.18M | 25.77% |
| 2020-12-31 | $124.18M | 5.37% |
| 2019-12-31 | $117.85M | 29.71% |
| 2018-12-31 | $90.86M | 42.13% |
| 2017-12-31 | $63.92M | 17.54% |
| 2016-12-31 | $54.38M | 6.28% |
| 2015-12-31 | $51.17M | 77.69% |
| 2014-12-31 | $28.80M | 151457.89% |
| 2013-12-31 | $19.00K | -9.52% |
| 2012-12-31 | $21.00K | 16.67% |
| 2011-12-31 | $18.00K | -79.78% |
| 2010-06-30 | $89.00K | -51.10% |
| 2009-06-30 | $182.00K | -65.13% |
| 2008-06-30 | $522.00K | -23.80% |
| 2007-06-30 | $685.00K | -20.63% |
| 2006-06-30 | $863.00K | -5.06% |
| 2005-06-30 | $909.00K | -30.18% |
| 2004-06-30 | $1.30M | 54.27% |
| 2003-06-30 | $844.00K | -3.76% |
| 2002-06-30 | $877.00K | -2.45% |
| 2001-06-30 | $899.00K | -21.83% |
| 2000-06-30 | $1.15M | 30.53% |
| 1999-06-30 | $881.00K | 253.82% |
| 1998-06-30 | $249.00K | -37.75% |
| 1997-06-30 | $400.00K | -75.00% |
| 1996-06-30 | $1.60M | - |
Vericel generated $197.52M in revenue during NA 2023, up 20.17% compared to the previous quarter, and up 217.39% compared to the same period a year ago.
Vericel Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $52.66M | 2.69% |
| 2024-03-31 | $51.28M | -21.10% |
| 2023-12-31 | $65.00M | 42.59% |
| 2023-09-30 | $45.58M | -0.74% |
| 2023-06-30 | $45.92M | 11.96% |
| 2023-03-31 | $41.02M | -22.16% |
| 2022-12-31 | $52.69M | 36.69% |
| 2022-09-30 | $38.55M | 4.06% |
| 2022-06-30 | $37.05M | 2.69% |
| 2022-03-31 | $36.07M | -24.20% |
| 2021-12-31 | $47.59M | 37.92% |
| 2021-09-30 | $34.51M | -12.69% |
| 2021-06-30 | $39.52M | 14.32% |
| 2021-03-31 | $34.57M | -23.57% |
| 2020-12-31 | $45.23M | 40.21% |
| 2020-09-30 | $32.26M | 61.18% |
| 2020-06-30 | $20.01M | -24.98% |
| 2020-03-31 | $26.68M | -32.27% |
| 2019-12-31 | $39.39M | 29.15% |
| 2019-09-30 | $30.50M | 16.63% |
| 2019-06-30 | $26.15M | 19.90% |
| 2019-03-31 | $21.81M | -30.40% |
| 2018-12-31 | $31.34M | 39.37% |
| 2018-09-30 | $22.48M | 18.27% |
| 2018-06-30 | $19.01M | 5.46% |
| 2018-03-31 | $18.03M | -22.80% |
| 2017-12-31 | $23.35M | 63.74% |
| 2017-09-30 | $14.26M | -15.89% |
| 2017-06-30 | $16.95M | 81.10% |
| 2017-03-31 | $9.36M | -43.35% |
| 2016-12-31 | $16.52M | 51.18% |
| 2016-09-30 | $10.93M | -14.77% |
| 2016-06-30 | $12.82M | -9.11% |
| 2016-03-31 | $14.11M | -8.51% |
| 2015-12-31 | $15.42M | 36.35% |
| 2015-09-30 | $11.31M | -16.78% |
| 2015-06-30 | $13.59M | 25.27% |
| 2015-03-31 | $10.85M | -26.23% |
| 2014-12-31 | $14.71M | 52.27% |
| 2014-09-30 | $9.66M | 117.92% |
| 2014-06-30 | $4.43M | 100.00% |
| 2014-03-31 | - | -100.00% |
| 2013-12-31 | $8.00K | 100.00% |
| 2013-09-30 | - | -100.00% |
| 2013-06-30 | $3.00K | -62.50% |
| 2013-03-31 | $8.00K | -57.89% |
| 2012-12-31 | $19.00K | 100.00% |
| 2012-09-30 | - | 100.00% |
| 2012-06-30 | - | -100.00% |
| 2012-03-31 | $2.00K | 100.00% |
| 2011-12-31 | - | -100.00% |
| 2011-09-30 | $9.00K | 100.00% |
| 2011-06-30 | - | -100.00% |
| 2011-03-31 | $9.00K | 100.00% |
| 2010-09-30 | - | 100.00% |
| 2010-06-30 | - | 100.00% |
| 2010-03-31 | - | -100.00% |
| 2009-12-31 | $16.00K | -78.08% |
| 2009-09-30 | $73.00K | 5.80% |
| 2009-06-30 | $69.00K | 18.97% |
| 2009-03-31 | $58.00K | 107.14% |
| 2008-12-31 | $28.00K | 3.70% |
| 2008-09-30 | $27.00K | -81.88% |
| 2008-06-30 | $149.00K | -26.24% |
| 2008-03-31 | $202.00K | - |
Vericel generated $52.66M in revenue during Q2 2024, up 2.69% compared to the previous quarter, and up 128.39% compared to the same period a year ago.
Vericel Revenue Breakdown
Vericel Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|---|
| MACI Implants And Kits | $164.80M | $131.97M | $111.55M | - |
| NexoBrid | - | - | - | $2.20M |
Vericel's latest annual revenue breakdown by segment (product or service), as of Dec 23: MACI Implants And Kits (100.00%).
Quarterly Revenue by Product
| Product/Service | Jun 24 | Mar 24 | Dec 23 | Jun 23 | Mar 23 | Sep 22 | Jun 22 | Mar 22 | Sep 21 | Jun 21 | Mar 21 | Sep 20 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | Mar 18 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MACI Implants And Kits | $44.13M | $40.18M | $94.27M | $36.34M | $34.19M | - | - | - | - | - | - | - | - | - | - | - | - | - |
| MACI Implants And Kits Member | - | - | - | - | - | $31.01M | $28.61M | $26.00M | - | - | - | - | - | - | - | - | - | - |
| MACI Implants and Kits, and Epicel | - | - | - | - | - | - | - | - | $33.72M | $38.68M | $33.63M | $31.02M | - | - | - | - | - | - |
| Product | - | - | - | - | - | - | - | - | - | - | - | - | $30.50M | $26.15M | $21.81M | $22.48M | $19.01M | - |
| Biopsy Kits | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $436.00K |
| Epicel | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $5.97M |
| Implants | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.01M |
Vericel's latest quarterly revenue breakdown by segment (product or service), as of Jun 24: MACI Implants And Kits (100.00%).
Vericel Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| BPMC | Blueprint Medicines | $249.38M | $138.16M |
| VCEL | Vericel | $197.52M | $52.66M |
| XNCR | Xencor | $168.34M | $16.96M |
| RGNX | REGENXBIO | $90.24M | $22.30M |
| MRUS | Merus | $43.95M | $7.33M |
| RLAY | Relay Therapeutics | $25.55M | - |
| IDYA | IDEAYA Biosciences | $23.39M | - |
| RVMD | Revolution Medicines, Inc. Warrant | $11.58M | - |
| CLGN | CollPlant Bio | $10.96M | $98.00K |
| MREO | Mereo BioPharma Group | $10.00M | - |
| STOK | Stoke Therapeutics | $8.78M | $4.22M |
| CYTK | Cytokinetics | $7.53M | $249.00K |
| CRNX | Crinetics Pharmaceuticals | $4.01M | $640.00K |
| IPSC | Century Therapeutics | $2.23M | $771.00K |
| PLRX | Pliant Therapeutics | $1.58M | - |
| CMRX | Chimerix | $324.00K | $129.00K |
| KROS | Keros Therapeutics | $151.00K | $83.00K |
| XFOR | X4 Pharmaceuticals | - | $563.00K |
| DAWN | Day One Biopharmaceuticals | - | $8.19M |
| DYN | Dyne Therapeutics | - | - |
| SNDX | Syndax Pharmaceuticals | - | $3.50M |
| TERN | Terns Pharmaceuticals | - | - |
VCEL Revenue FAQ
What is Vericel’s yearly revenue?
Vericel's yearly revenue for 2023 was $197.52M, representing an increase of 20.17% compared to 2022. The company's yearly revenue for 2022 was $164.36M, representing an increase of 5.24% compared to 2021. VCEL's yearly revenue for 2021 was $156.18M, representing an increase of 25.77% compared to 2020.
What is Vericel’s quarterly revenue?
Vericel's quarterly revenue for Q2 2024 was $52.66M, a 2.69% increase from the previous quarter (Q1 2024), and a 14.68% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $51.28M, a -21.10% decrease from the previous quarter (Q4 2023), and a 25.02% increase year-over-year (Q1 2023). VCEL's quarterly revenue for Q4 2023 was $65M, a 42.59% increase from the previous quarter (Q3 2023), and a 23.35% increase year-over-year (Q4 2022).
What is Vericel’s revenue growth rate?
Vericel's revenue growth rate for the last 3 years (2021-2023) was 26.46%, and for the last 5 years (2019-2023) was 67.60%.
What are Vericel’s revenue streams?
Vericel's revenue streams in c 23 are MACI Implants And Kits
What is Vericel’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Vericel was MACI Implants And Kits. This segment made a revenue of $164.8M, representing 100.00% of the company's total revenue.